Rhumbline Advisers Has $250.26 Million Holdings in Stryker Corporation $SYK

Rhumbline Advisers decreased its position in shares of Stryker Corporation (NYSE:SYK) by 4.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 632,569 shares of the medical technology company’s stock after selling 29,619 shares during the period. Rhumbline Advisers owned 0.17% of Stryker worth $250,263,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in SYK. Vanguard Group Inc. lifted its position in shares of Stryker by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock worth $13,253,831,000 after purchasing an additional 440,607 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Stryker by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after buying an additional 1,021,496 shares during the last quarter. Geode Capital Management LLC increased its position in Stryker by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock worth $2,910,445,000 after buying an additional 79,654 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Stryker by 13.1% during the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after buying an additional 261,058 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Stryker by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock valued at $776,871,000 after acquiring an additional 83,954 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of Stryker stock opened at $368.35 on Friday. The firm has a market cap of $140.87 billion, a P/E ratio of 48.79, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The firm’s 50-day simple moving average is $369.38 and its 200-day simple moving average is $380.68. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Rothschild Redb raised shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Truist Financial raised their price target on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research report on Friday, November 14th. Wells Fargo & Company upped their price objective on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Barclays increased their target price on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Finally, Needham & Company LLC restated a “buy” rating and set a $448.00 price target on shares of Stryker in a research note on Friday, November 14th. Thirteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $434.37.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 522,618 shares of company stock worth $185,577,237 in the last quarter. Corporate insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.